Evidence map›Paper›PMID 37760826›Full record

ArticleBiomedicines2023

A New Cu/Fe Layer Double Hydroxide Nanocomposite Exerts Anticancer Effects against PC-3 Cells by Inducing Cell Cycle Arrest and Apoptosis.

Mohamed Y Zaky, Rehab Mahmoud, Ahmed A Farghali, Hany Abd El-Raheem, Ahmed Hassaballa, Mohamed Mohany, Dalal Hussien M Alkhalifah, Wael N Hozzein, Abdelrahman Mohamed

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Mohamed Y ZakyMolecular Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef 62511, Egypt.ORCID 0000-0002-2387-593X
Rehab MahmoudChemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef 62511, Egypt.
Ahmed A FarghaliMaterials Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Science (PSAS), Beni-Suef University, Beni-Suef 62511, Egypt.
Hany Abd El-RaheemMaterials Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Science (PSAS), Beni-Suef University, Beni-Suef 62511, Egypt.ORCID 0000-0003-4076-3152
Ahmed HassaballaNutrition and Food Science, College of Liberal Arts and Sciences, Wayne State University, Detroit, MI 48202, USA.
Mohamed MohanyDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-7709-5253
Dalal Hussien M AlkhalifahDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia.
Wael N HozzeinBotany and Microbiology Department, Faculty of Science, Beni-Suef University, Beni-Suef 62511, Egypt.ORCID 0000-0003-2467-9719
Abdelrahman MohamedChemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef 62511, Egypt.
Beni-Suef University · EGKing Saud University · SAPrincess Nourah bint Abdulrahman University · SAWayne State University · US

Funding

Princess Nourah bint Abdulrahman University PNURSP2023R15
6 · The paper itself

Abstract

Prostate cancer treatment poses significant challenges due to its varying aggressiveness, potential for metastasis, and the complexity of treatment options. Balancing the effectiveness of therapies, minimizing side effects, and personalizing treatment strategies are ongoing challenges in managing this disease. Significant advances in the use of nanotechnology for the treatment of prostate cancer with high specificity, sensitivity, and efficacy have recently been made. This study aimed to synthesize and characterize a novel Cu/Fe layer double hydroxide (LDH) nanocomposite for use as an anticancer agent to treat prostate cancer. Cu/Fe LDH nanocomposites with a molar ratio of 5:1 were developed using a simple co-precipitation approach. FT-IR, XRD, SEM, TEM, TGA, and zeta potential analyses confirmed the nanocomposite. Moreover, the MTT cell viability assay, scratch assay, and flow cytometry were utilized to examine the prospective anticancer potential of Cu/Fe LDH on a prostate cancer (PC-3) cell line. We found that Cu/Fe LDH reduced cell viability, inhibited cell migration, induced G

Indexed as

apoptosiscell cycle arrestCu/Fe LDHprostate cancer

Identifiers

PMID37760826
PMCPMC10525695
OpenAlexW4386222695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.